Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Clinical study

ICI toxicity profiles in patients with advanced head and neck cancer

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Toxicity profiles of immune checkpoint inhibitors (ICIs) in patients with advanced head and neck squamous cell cancer vary between programmed cell death protein 1 (PD-1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors and ICI combination therapy, according to findings of a study published in Cancer Medicine.
Literatur
Zurück zum Zitat Dang S, et al. Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis Cancer Medicine : 30 Mar 2024. Available from: URL: https://doi.org/10.1002/cam4.7119 Dang S, et al. Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis Cancer Medicine : 30 Mar 2024. Available from: URL: https://​doi.​org/​10.​1002/​cam4.​7119
Metadaten
Titel
ICI toxicity profiles in patients with advanced head and neck cancer
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-57103-3

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Imatinib

Case report

Multiple drugs

Case report

COVID-19-vaccine

Case report

Antineoplastics

Case report

Testosterone

Case report

Multiple drugs